![Courtney Dugan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Courtney Dugan
Investor Relations Kontakt bei
YMAS THER
Profil
Ms. Courtney Dugan is a Vice President-Investor Relations at Y-mAbs Therapeutics, Inc. and an Investor Relations Contact at Immuneering Corp.
Ms. Dugan was previously employed as a Vice President-Investor Relations by Pyxis Oncology, Inc. and a Vice President-Healthcare Investor Relations by ICR LLC.
Aktive Positionen von Courtney Dugan
| Unternehmen | Position | Beginn |
|---|---|---|
| YMAS THER | Investor Relations Kontakt | 01.05.2023 |
| IMMUNEERING CORPORATION | Investor Relations Kontakt | - |
Ehemalige bekannte Positionen von Courtney Dugan
| Unternehmen | Position | Ende |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Investor Relations Kontakt | 01.10.2022 |
ICR LLC
 ICR LLC Miscellaneous Commercial ServicesCommercial Services Operates as a strategic communications and advisory ?rm | Public Communications Contact | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
48
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
ICR LLC
ICR LLC Miscellaneous Commercial ServicesCommercial Services Operates as a strategic communications and advisory ?rm | Commercial Services |
Immuneering Corp.
 Immuneering Corp. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, focuses on the oncology and neuroscience product candidates | Health Technology |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
